CSPC PHARMA (01093): The Phase I/II clinical trial of SYS6062 for the treatment of advanced solid tumors has officially launched at its first study site in China.

CSPC PHARMA (01093) announced that the Phase I/II clinical trial of SYS6062 (the product), developed by the group for the treatment of advanced solid tumors, has officially launched at its first study site in China. The product is an antibody-drug conjugate (ADC) developed by the group that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Its antibody component can specifically bind to the surface of tumor cells expressing CEACAM5 and be internalized into the cells, whereupon the small-molecule toxin is released through protease-specific cleavage, thereby killing the tumor cells; at the same time, the product can exert a bystander effect, non-specifically killing surrounding tumor cells. The group obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration of the People's Republic of China in October 2026, and after approval initiated a multicenter, open-label, dose-escalation, pharmacokinetic (PK) expansion and cohort expansion first-in-human Phase I/II clinical trial, aimed at evaluating the safety, tolerability, PK characteristics and preliminary antitumor efficacy of the product in patients with advanced solid tumors. Currently, participant recruitment and screening for the clinical trial are being actively advanced.